Recent advances in recombinant DNA technology have led to an increase in our understanding of the molecular basis of many genetic diseases. Approximately 3500 different human genetic diseases are known, and as the genes responsible for these diseases are identified and cloned, many advances in treatment and maintenance will be made. These advances have already translated into improved methods for the prenatal diagnosis of many diseases and the use of recombinant gene products in treatment regimes. It is envisaged, however, that with further developments it will soon be possible to correct the genetic defects themselves in affected individuals, through the use of somatic gene therapy techniques. The potential for this form of treatment has generated much interest and the possible applications of somatic gene therapy have been much discussed."' For the purposes of this annotation, however, we are confining the discussion to those genetic diseases which are currently treated by bone marrow transplantation.
Somatic gene therapy is defined as the correction of a defective or absent gene with its cloned functional equivalent. It differs from germline gene therapy in that the gene is only introduced into the somatic cells of the patient and not into the germline (that is, sperm or ova). Therefore, the gene can only be expressed in those cells into which it was introduced and their progeny cells, but it cannot be passed on to subsequent generations of children.
Most cases of genetic disease are the result of a point mutation rather than a gene deletion, and this means that the defective gene is still present, though not necessarily active, in the affected cells. Therefore, the introduction of a functional gene in addition to the defective gene would result in gene augmentation. However, because of the nonspecific nature of the integration event where the gene is inserted randomly into the human genome, a variety of problems may arise. These could include non-expression of the introduced gene or insertional mutagenesis, whereby a normally active gene is silenced or a silent deleterious gene may become activated. Despite 18 It will probably be necessary to define the nature of the defect in individual cases as in the small number of families where a gene deletion rather than a point mutation exists the product of the introduced gene may prove to be immunogenic, thereby rendering the treatment ineffective. The techniques currently being developed allow the potential for insertional oncogenesis, as they all rely on random integration events. The only foreseeable way to overcome this problem is by gene targeting but this remains only a theoretical possibility at present.
In view of these problems, somatic gene therapy should, at present, only be considered for diseases that are fatal in early infancy or that carry a very poor prognosis with the currently available treatments. There needs to be an ethical debate in the United Kingdom to discuss issues well before the first attempt at treatment are contemplated. In the United States the machinery to obtain ethical approval is already in place whereby permission needs to be obtained from national bodies. No such national body exists in the United Kingdom and there is the potential risk that such treatments will be carried out under the approval only of individual hospital ethical committees, the performance of which may vary widely. The European Medical Research Councils made a joint statement over a year ago to the effect that a national body in each country should consider all proposals for human gene therapy and ensure the application of agreed national guidelines. They recommended that early trials should be monitored by a central body. ' 
